Instructions for Credit Participation in this self-study activity should be completed in approximately 4.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from September 26, 2025 through September 26, 2026:

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Visit https://paceducation.com/CES25   
  4. Complete the activity evaluation

Jointly provided by Partners for Advancing Clinical Education and American Sexual Health Association

Estimated time to complete the activity – 4.0 hours

For additional information about the accreditation of this activity, please visit https://partnersed.com

Target Audience

This activity is intended for physicians, registered nurses, physician’s associate, physician assistant, nurse practitioner, other APRN.

Educational Objectives                                                   

Upon completion of this activity, participants should be able to:

  • Learn how to identify and treat patients with drug resistant Trichomonas vaginalis infection
  • Understand how to treat Trichomonas infection in the setting of 5-nitroimidazole hypersensitivity
  • Discuss the treatment of recurrent BV, including male partner treatment in some circumstances
  • Discuss the treatment of compicated cases of vulvovaginal candidiasis

Faculty

  • Jennifer Karlin, MD, PhD: University of California, San Francisco
  • Christina Muzny, MD, MPH: UAB
  • Chase Cannon, MD, MPH: University of Washington
  • Shannon Winters, MN, ANP-BC, ARNP: Seattle & King County Public Health Sexual Health Clinic
  • Antoinette Nguyen, MD: Emory University
  • Kathryn Curtis, PhD

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

  • Jennifer Karlin, MD, PhD has no relevant financial relationships.
  • Christina Muzny, MD, MPH, faculty for this educational activity, has the following relevant financial relationships:
    • Consultant, advisor, or speaker for BioNTech
    • Consultant, advisor, or speaker for Abbott
    • Consultant, advisor, or speaker for biomerieux
    • Consultant, advisor, or speaker for Becton Dickinson
    • Research for Gilead
    • Research for Aim Max Therapeutics
    • Editorial Board Member for Merck Manuals
    • Royalties on vaginitis section review for UpToDate
  • Chase Cannon, MD, MPH, faculty for this educational activity, has the following relevant financial relationship:
    • Researcher for Hologic
  • Shannon Winters, MN, ANP-BC, ARNP, faculty for this activity, has no relevant financial relationships.
  • Antoinette Nguyen, MD, faculty for this activity, has no relevant financial relationships.
  • Kathryn Curtis, PhD, faculty for this activity, has no relevant financial relationships.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and American Sexual Health Association.  Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 4.0 contact hours.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.